FGBweb_BFGBweb_BFGBweb_BFGBweb_B
  • THE FOUNDATION
    • About Us
    • Background
    • Our Mission
    • Contact Us
  • PROGRAMS
    • Fellowships
    • Research
  • NEWS & UPDATES
    • News
    • Press Area
  • VIDEO
English
  • Italiano
✕
How to predict breast cancer therapy response
10/01/2022
Advanced melanoma, encouraging results with relatlimab e nivolumab
24/01/2022

Lung cancer benefits from the combination of EGFR-TK inhibitors and patritumab deruxtecan

Published by Fondazione Gianni Bonadonna at 17/01/2022
Categories
  • Events
  • Uncategorized
Tags

    In EGFR-mutated non-small cell lung cancer a combination therapy could be an option because EGFR-TKIs increase HER3 expression

    Patritumab deruxtecan, a potential first-in-class HER3 directed antibody drug conjugate, could have more anticancer activity in combination with a EGFR-tyrosine kinase inhibitor (EGFR-TKI): a new paper on Clinical Cancer Research shows that EGFR-TKIs increase HER3 expression thus enhancing anticancer activity of HER-3 targeting patritumab deruxtecan.

    The study has been conducted on tumor samples obtained from patients with EGFR-mutated non-small cell lung cancer treated with EGFR-TKI, the standard first line therapy for these tumors. All tumors eventually acquire resistance to EGFR-TKIs and when it happens, treatment options are limited. However, clinical trials have demonstrated that the HER3-targeting antibody–drug conjugate patritumab deruxtecan has some benefits in patients with EGFR-mutated non-small cell lung cancer: that’s why authors tried to understand the mechanisms regulating the expression of patritumab deruxtecan target, HER3, and to verify if there could be a way to enhance its anticancer activity by modifying HER3 expression. Data shows an augmented HER3 expression in EGFR- mutated tumors with acquired EGFR-TKI resistance compared with paired pretreatment samples, moreover in vitro testing also showed that EGFR-TKI directly increased HER3 expression and enhanced the anticancer activity of patritumab deruxtecan.

    The findings, authors say, highlights a rational for combination therapy with EGFR-TKI and patritumab deruxtecan because the first treatment, even inducing resistance, could enhance the anticancer activity of the second: HER3 expression was increased by EGFR-TKI therapy and augmentation was likely mediated by PI3K/AKT/mTOR signaling. In December 2021 the US Food and Drug Administration has granted breakthrough therapy designation to patritumab deruxtecan for the treatment of patients with metastatic or locally advanced EGFR-mutated non-small cell lung cancer with disease progression on or after treatment with a third-generation tyrosine kinase inhibitor and platinum-based therapies.

    Share
    0

    Related posts

    cancer cell made in 3d software

    29/05/2023

    Olaparib in metastatic prostate cancer with BRCA1/2 mutations


    Read more
    19/05/2023

    The fellowships in memory of Gianni Bonadonna: an opportunity for growth


    Read more
    15/05/2023

    An immunotherapy combination for colorectal cancer


    Read more

    Follow us

    LinkedIn | Facebook | Twitter
    • Privacy policy
    • Cookie policy
    © 2021 - Fondazione Gianni Bonadonna
      English
      • Italiano
      • English